Stay ConnectedPodcast interviews with genius-level (top .1%) practitioners, scientists, researchers, clinicians and professionals in Cancer, 3D Bio Printing, CRISPR-CAS9, Ketogenic Diets, the Microbiome, Extracellular Vesicles, and more.
Subscribe today for the latest medical, health and bioscience insights from geniuses in their field(s).
Copyright: © Richard Jacobs
All humans are susceptible to breathing problems—regardless of age, health status, or lifestyle. Why is this so? According to Dr. Steven Park, it's a pretty simple reason: we can talk. In order to talk, the soft tissues in the throat have to be exactly that—soft or "floppy." This softness, while allowing for speech, also makes the tissue susceptible to caving while we sleep, which leads to snoring.
When the tissues cave entirely, a person stops breathing altogether, and may or may not develop sleep apnea. Both snoring and sleep apnea expose people to a greater risk of stroke, high blood pressure, cancer, diabetes, weight gain, acid reflux, sinus infections, fatigue, anxiety, headaches…the list continues.
Over the course of his career as an ear, nose, and throat doctor, Steven Park has seen countless patients whose problems were in one way or another related to their quality of sleep, and he aims to educate people on the causes and effects of snoring.
On today's episode, Dr. Park discusses a number of fascinating topics that likely have some relevance to your life or the lives of your loved ones. Tune in to discover:
Press play to learn more and be sure to check out Dr. Park's book, Sleep Interrupted: A Physician Reveals the #1 Reason Why So Many Of Us Are Sick and Tired.
Rob Taub is not only a respected figure in film, radio, television, and journalism but also an advocate for type 2 diabetes and ambassador for a joint venture between the American Heart Association and American Diabetes Association called Know Diabetes By Heart, which aims to educate people about diabetes and heart disease.
Taub believes that a lack of understanding surrounding the body and how it functions in sickness and in health, as well as what it needs in order to function properly, greatly contributes to the growing sickness of American adults and kids today.
On today's episode, you will learn:
Learn more by visiting knowdiabetesbyheart.org.
Nearly half of the adult U.S. population suffers from some form of periodontal disease, which can result in the rapid destruction or slow reduction of bone, inflamed soft tissues, abscesses, and tooth loss. In the past, bone grafting—a procedure which is both time-consuming and expensive—was the only known method of getting bone back in the places where it should be.
Now, a different technology is available: low-level laser therapy (LLLT). With the use of LLLT, bone regrowth can be obtained for less money, in less time, and provides more comfort to the patient than bone grafting and accelerated orthodontics techniques. But that's not all: the benefits of low-level laser therapy are wide-ranging, and have been shown to be effective in treating nearly any ailment which can improve with tissue regeneration. The technology has been used in both human and veterinary medicine, and shows great promise as a safe, affordable, and effective medical treatment.
On today's episode, Dr. John Hendy joins the podcast to discuss all the ins and outs of LLLT, including how he has incorporated it into his work with patients.
By tuning in, you will learn:
In recent years, interest in organoid technology has exploded. More than ever before, scientists, researchers, and the public at large are beginning to appreciate the value that organoids can contribute to the understanding and clinical treatment of diseases, as well as drug development.
In 2009, the first-ever paper on this technology was published, and on today's episode, CEO of Hubrecht Organoid Technology (HUB) in the Netherlands, Robert Vries, PhD dives into the details and complexity of how it's grown since then. He explores with us the different types and functions of organoids, how they are made, and where this field of research is headed in the near future.
Interested in the details of all this and more? Tune in to discover:
For more information, check out https://hub4organoids.eu/.
Associate Professor in the Computer Science and Operations Research Department at the University of Montreal, Irina Rish, PhD focuses her work on the intersection between artificial intelligence (AI) and neuroscience, researching the ways in which our knowledge of neuroscience can improve AI, and how AI models can aid our understanding of neuroscience.
On today's podcast, you will discover:
Learn more about Dr. Rish's work by visiting https://mila.quebec/en/person/irina-rish/.
Eduard Willms, Postdoctoral Scientist at La Trobe University, Melbourne, Australia, provides an overview of the types of extracellular vesicles, and the role of extracellular vesicles (EVs).
Willms research is focused on the role of extracellular vesicles (EVs) in cellular communication. Willms holds a BSc in Pharmacy and a DPhil in Physiology. He has intensively studied EV heterogeneity in an effort to more fully understand the specific roles of various types of EVs released by cells.
Willms explains how he got into the study of exosomes—membrane bound extracellular vesicles that are created in the endosomal compartment of nearly all eukaryotic cells. Starting with some fascinating early experiments during his education years studying pharmacy, Willms was intrigued by what he was learning, and was hooked on cellular study from then on. Willms explains cellular communication, discussing hormones and neurotransmitters, etc. Willms talks about his interest in extracellular vesicle heterogeneity, and looking at what types of vesicles are secreted by cells. What kind of vesicle is able to enter a cell and deliver its messages? Willms talks about how the systems work, and how EVs might be used to deliver therapeutics or drugs into the cells. As he states, it is important to know which kinds of vesicles could be successful in delivering these messages, and ultimately—deliver therapeutics.
Continuing, the noted research scientist expounds upon the cellular environments and discusses possible stability issues in regard to EVs. He talks about biodistribution in lab studies and the life of EVs, essentially concerned with how long they can perform these important duties. Wrapping up, Willms discusses what they have observed in various populations of vesicles, and the relative possibilities, explaining organelles and structures.
In this podcast:
What are extracellular vesicles?
How can EVs be used to deliver therapeutics into cells?
How do cells communicate?
Not more than twenty years ago, only four or five blood cancers could be defined; today, hundreds of different types of lymphoma, leukemia, and myeloma cancers have been characterized—each one with a unique molecular structure and genome. As a result, an enormous amount of data has become available in the area of research and development for cancer drugs.
According to Panna Sharma, CEO of Lantern Pharma, there is no better place to apply the tools of machine learning and artificial intelligence (AI). "There could be more permutations of chemical compounds than there are galaxies, so it's a perfect problem area for AI," says Sharma.
He goes on to explain why some drugs—despite being extremely effective for some people—don't stay on the market. In addition to depriving patients access to a drug which could truly help them, this also represents a significant financial loss, considering that hundreds of millions of dollars can go into the development of a single cancer drug.
The technology being employed by Lantern Pharma has the ability to identify which drugs have worked for some people in the past, why they worked, and how to use this information as a predictive measure of what may (or may not) work for any given patient with a particular type of cancer. Sharma is a wealth of knowledge, and discusses the details of all this and more, including:
Learn more at https://www.lanternpharma.com/.
When you think of what addiction recovery looks like, you probably don't envision the consumption of psychedelic drugs. On today's episode, Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins and author of 47 articles on psychedelic drugs, Matthew Johnson, PhD, explains why and how psychedelic therapy might have a place in addiction recovery after all.
His area of expertise lies in understanding the ways in which psychedelic drugs can serve as behavior change agents. This idea is consistent with neuroscience research findings, countless anecdotal stories, and ceremonial use of psychedelic substances in a variety of indigenous cultures. Intrigued by the idea? Tune in to hear all the details and learn more, including:
Tune in to hear the full discussion.
Dr. Christian Regenbrecht, shareholder, CEO, of CELLphenomics, provides an overview of his company's important work that could assist researchers as they strive to develop new drugs to treat disease.
Regenbrecht studied biology and philosophy at the University of Bonn, and continued his postdoc with noted scientist, Hans Lehrach, at the Max Planck Institute for Molecular Genomics in Berlin. Regenbrecht has focused some of his time on improved patient-derived in vitro models, culture technologies, and preclinical efficacy studies.
Regenbrecht discusses his extensive work and the innovations that are happening at CELLphenomics. With greater than 400 proprietary patient-derived 3D (PD3D®) cell cultures, CELLphenomics can offer researchers an opportunity to test compounds with a comprehensive screening approach in an, up to, 384 well format. In simplest terms, patient-derived cell cultures are essentially novel multicellular systems newly isolated from primary organs through mechanical and enzymatic dissociation. Within a system such as this, cells that are grown on a proprietary matrix can develop as 3D organoids which are composed of cell clusters preserving the uniquely complex composition of the tissue of origin.
Regenbrecht discusses cell types in tumors, specifically focusing on colon tumors. Continuing, he discusses the ways that tumors can metastasize. Regenbrecht explains how they are able to use their processes to isolate exosomes that are secreted into the cell culture. By studying this information, researchers may be able to predict where the next site of metastasization could occur. Regenbrecht explains their mission at CELLphenomics, as a state-of-the-art in vitro service provider positioned to offer high-quality, sensibly priced cell culture models and ultimately assist the biotech and pharma industries to create innovative testings of new anti-cancer drugs.
In this podcast:
What makes some tumors metastasize?
A detailed explanation of exosomes
Innovative practices in the biotech industry
Imagine increasing your business' retention rates by 28.9%, and increasing them by over 20% within the first week of making an investment. With a new machine learning application from Bellwethr, you can.
CEO and founder, Matt Moody, joins the podcast to discuss the importance of customer retention and how Bellwethr is making it happen. Compelled by the belief that everyone should have access to the power of artificial intelligence (AI) and the motivation to show his customers the range of problems that AI can solve, Matt Moody and his team at Bellwethr are making it easier than ever for businesses and individuals to benefit from this technology. Tune in to learn more, including:
Check out https://www.bellwethr.com/ to learn more.
Our TOPPODCAST Picks 
